Cardiovascular Drugs and Therapy

, Volume 29, Issue 6, pp 551–561 | Cite as

Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial

  • Lidia Staszewsky
  • Serge Masson
  • Simona Barlera
  • Marcello Disertori
  • Silvana Boni
  • Daniele Bertoli
  • Olga Vriz
  • Elena Pasotti
  • Prisca Zeni
  • Tarcisio Vago
  • Aldo P. Maggioni
  • Gianni Tognoni
  • Roberto Latini
  • on the behalf of the GISSI-AF Investigators



Atrial fibrillation (AF) is the most common arrhythmia and has an increasing impact on public health because of its morbidity and mortality. Clinical and diagnostic tests to predict the recurrence of arrhythmia and clinical events before AF becomes permanent are still an open issue.


307 out of 1442 patients in sinus rhythm, at high risk of recurrence of AF enrolled in the GISSI-AF study, participated in a substudy with echocardiographic and biohumoral evaluation at baseline and at 12-month follow-up. The relations between biomarker concentrations and echocardiographic parameters with study endpoints in 1 year, were analysed by a stepwise multivariable Cox model (entry criteria p < 0.5 and stay criteria p < 0.2).


The echocardiographic variables, cardiac markers and clinical variables considered in the statistical model indicated a higher concentration of NT-proBNP at baseline as the strongest factor related to time of first AF recurrence (HR 1.42; 95 %CI 1.23–1.46), first CV hospitalization (HR 1.58; 95 %CI 1.31–1.92) and increasing duration of recurrent AF (OR 2.16; 95 %CI 1.52–3.08). Valsartan treatment was not related to clinical events.


In patients in sinus rhythm with a history of AF a higher concentration of NT-proBNP at baseline was the strongest independent risk factor for first AF recurrence and its duration, and for the first hospital admission for cardiovascular reasons.


Atrial fibrillation Echocardiography Circulating biomarkers Natriuretic peptides Atrial fibrillation recurrence Hospitalizations Clinical trial 



We thank the patients, nurses and cardiologists who participated in the echocardiographic and biohumoral substudy of GISSI-AF. We are grateful to J.D. Baggott for language editing.

Compliance with Ethical standards

Funding sources

The GISSI Studies and this substudy are supported by Associazione Nazionale Medici Cardiologi Ospedalieri and by IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”. Funding was provided by Novartis, which had no role in the design or conduction of the trial, the collection, analysis, or interpretation of the data; or the writing of the report. Reagents for measuring circulating biomarkers were kindly provided by B.R.A.H.M.S. AG and Roche Diagnostics GmbH.

Conflict of interests and disclosures

Drs. Masson, Staszewsky, Maggioni, Disertori and Latini received institutional research support from Novartis Pharma, the company that funded the GISSI-AF trial.


  1. 1.
    Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129:837–47.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Camm AJ, Lip GY, De Caterina R, et al. ESC committee for practice guidelines-CPG; document reviewers. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace. 2012;14:1385–413.CrossRefPubMedGoogle Scholar
  3. 3.
    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64:e1–76.Google Scholar
  4. 4.
    Hijazi Z, Oldgren J, Andersson U, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation. 2012;125:1605–16.CrossRefPubMedGoogle Scholar
  5. 5.
    Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61:2274–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Hijazi Z, Siegbahn A, Andersson U, et al. ARISTOTLE investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014;100:1193–200.CrossRefPubMedGoogle Scholar
  8. 8.
    Disertori M, Latini R, Barlera S, et al. The GISSI-AF investigators.Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17. Erratum in: N Engl J Med. 2009;360:2379.CrossRefPubMedGoogle Scholar
  9. 9.
    Disertori M, Lombardi F, Barlera S, et al. GISSI-AF investigators. Clinical predictors of atrial fibrillation recurrence in the gruppo italiano per lo studio della sopravvivenza nell’Infarto miocardico-atrial fibrillation (GISSI-AF) trial. Am Heart J. 2010;159:857–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Disertori M, Latini R, Maggioni AP, et al. GISSI-AF investigators. Rationale and design of the GISSI-atrial fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown). 2006;7:29–38.CrossRefGoogle Scholar
  11. 11.
    Lang RM, Bierig M, Devereux RB, et al. Chamber quantification writing group; american society of Echocardiography’s guidelines and standards committee; european association of echocardiography. Recommendations for chamber quantification: a report from the american society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Staszewsky L, Wong M, Masson S, et al. GISSI-AF investigators. Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy. Circ Cardiovasc Imaging. 2011;4:721–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C, et al. Latini R; GISSI-AF investigators. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart. 2010;96:1909–14.CrossRefPubMedGoogle Scholar
  14. 14.
    Latini R, Masson S, Pirelli S, et al. GISSI-A investigators. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med. 2011;269:160–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Letsas KP, Filippatos GS, Pappas LK, et al. Determinants of plasma NT-pro-BNP levels in patients with atria fibrillation and preserved left ventricular ejection fraction. Clin Res Cardiol. 2009;98:101–16.CrossRefPubMedGoogle Scholar
  16. 16.
    Hussein AA, Saliba WI, Martin DO, et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation. 2011;123:2077–82.CrossRefPubMedGoogle Scholar
  17. 17.
    Therkelsen SK, Groenning BA, Kjaer A, Svendsen JH, Boje JG. ANP and BNP in atrial fibrillation before and after cardioversion--and their relationship to cardiac volume and function. Int J Cardiol. 2008;127:396–409.CrossRefPubMedGoogle Scholar
  18. 18.
    Schnabel RB, Wild PS, Wilde S, et al. Multiple biomarkers and atrial fibrillation in the general population. PLoS One. 2014;17:9e112486.Google Scholar
  19. 19.
    Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121:200–7.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Knudsen CW, Omland T, Clopton P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005;46:838–44.CrossRefPubMedGoogle Scholar
  22. 22.
    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Ellinor PT, Low AF, Patton KK, Shea MA, Macrae CA. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol. 2005;45:82–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Pikkarainen S, Tokola H, Kerkelä R, Majalahti-Palviainen T, Vuolteenaho O, Ruskoaho H. Endothelin-1-specific activation of B-type natriuretic peptide gene via p38 mitogen-activated protein kinase and nuclear ETS factors. J Biol Chem. 2003;278:3969–75.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Lidia Staszewsky
    • 1
  • Serge Masson
    • 1
  • Simona Barlera
    • 1
  • Marcello Disertori
    • 2
  • Silvana Boni
    • 3
  • Daniele Bertoli
    • 4
  • Olga Vriz
    • 5
  • Elena Pasotti
    • 6
  • Prisca Zeni
    • 2
  • Tarcisio Vago
    • 7
  • Aldo P. Maggioni
    • 8
  • Gianni Tognoni
    • 1
  • Roberto Latini
    • 1
  • on the behalf of the GISSI-AF Investigators
  1. 1.IRCCS-Istituto di Ricerche Farmacologiche “MarioNegri”MilanItaly
  2. 2.Ospedale Santa ChiaraTrentoItaly
  3. 3.Ospedale Civile San BiagioBovoloneItaly
  4. 4.Ospedale San Bartolomeo U.OSanta CaterinaItaly
  5. 5.Ospedale San AntonioSan Daniele del FriuliItaly
  6. 6.Cardiocentro TicinoLuganoSwitzerland
  7. 7.Ospedale Luigi SaccoMilanItaly
  8. 8.ANMCO Research CenterFlorenceItaly

Personalised recommendations